Vaccine
AssigneeSmithKline Beecham Biologicals s.a.
InventorsBrigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Vincent Vande Velde
Life of this patent
Estimating the term…
Abstract
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
Claims24
A vaccine composition comprising a live attenuated human rotavirus population that was serially passaged in cell culture, comprising a single variant defined by a nucleotide sequence encoding both of the major viral proteins designated as VP4 and VP7 admixed with a suitable pharmaceutical carrier or adjuvant, wherein the single variant is a variant wherein the VP4 gene comprises the following three substitutions:
- an adenine (A) at position 788;
- an adenine (A) at position 802;
- and a thymine (T) at position 501 from the start codon, and wherein the VP7 gene comprises the following three substitutions:
- a thymine (T) at position 605, an adenine (A) at position 897, and an adenine (A) at position 108 from the start codon.
A vaccine composition comprising a live attenuated rotavirus population designated as P43 that was serially passaged in cell culture, and is deposited under accession number ECACC 99081301.
Dependencies are inferred from the claim text.